Department of Nursing, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jpn J Nurs Sci. 2023 Jul;20(3):e12531. doi: 10.1111/jjns.12531. Epub 2023 Mar 24.
Chemotherapy-induced peripheral neuropathy limits cancer survivors' compliance with chemotherapy and impaired function. This study aimed to examine separate impacts of clinician-assessed, patient-reported sensory and motor chemotherapy-induced peripheral neuropathy on physical/role function and functional interference in advanced colorectal cancer survivors receiving chemotherapy.
A cross-sectional, correlational design utilizing convenience sampling enrolled 75 stage III or IV colorectal cancer adults undergoing chemotherapy. Participants filled out the Patient Neurotoxicity Questionnaire, Identification Pain Questionnaire, and Peripheral Neuropathy Scale. Then, a trained research nurse conducted a brief neurological assessment using the Total Neuropathy Scale - clinical version.
The prevalence of sensory and motor chemotherapy-induced peripheral neuropathy was from 34.7% to 54.7% and from 16.0% to 17.3%, respectively. Further, 20% of participants suffered from neuropathic pain. A low correlation between clinician-assessed and patient-reported chemotherapy-induced peripheral neuropathy was detected. The function was significantly impacted by patient-reported motor chemotherapy-induced peripheral neuropathy.
This study was superior in utilizing the brief and valid patient-reported and clinician-assessed tools to measure sensory and motor chemotherapy-induced peripheral neuropathy. Moreover, the identification of patient-reported motor symptoms has the largest influence on function in advanced colorectal cancer survivors. Nurses may use the brief and easily administered tools in clinical settings for effective screening and early detection of motor and sensory chemotherapy-induced peripheral neuropathy to prevent functional decline in advanced colorectal cancer survivors. However, this study was still limited because of the cross-sectional design, small sample size, sample heterogeneity, and recruiting participants from only one medical center.
化疗引起的周围神经病变限制了癌症幸存者对化疗的依从性，并损害了其功能。本研究旨在检查临床医生评估的、患者报告的感觉和运动性化疗引起的周围神经病变对接受化疗的晚期结直肠癌幸存者的身体/角色功能和功能障碍的单独影响。
本研究采用横断面相关性设计，利用便利抽样法招募了 75 名正在接受化疗的 III 或 IV 期结直肠癌成年人。参与者填写了患者神经毒性问卷、识别疼痛问卷和周围神经病变量表。然后，一名经过培训的研究护士使用总神经病变量表-临床版对患者进行了简短的神经学评估。
感觉和运动性化疗引起的周围神经病变的患病率分别为 34.7%至 54.7%和 16.0%至 17.3%。此外，20%的参与者患有神经性疼痛。临床医生评估的和患者报告的化疗引起的周围神经病变之间相关性较低。功能明显受到患者报告的运动性化疗引起的周围神经病变的影响。
本研究利用简短有效的患者报告和临床评估工具来测量感觉和运动性化疗引起的周围神经病变，具有优势。此外，患者报告的运动症状的识别对晚期结直肠癌幸存者的功能影响最大。护士可以在临床环境中使用这些简单易行的工具进行有效的筛查和早期检测运动性和感觉性化疗引起的周围神经病变，以防止晚期结直肠癌幸存者的功能下降。然而，由于横断面设计、样本量小、样本异质性以及仅从一个医疗中心招募参与者，本研究仍存在局限性。
